With the massive size of the cholesterol-lowering drug market, these results beg the question: Could MK-0616 be the next hit ...

Coronary heart disease (CHD) is a leading cause of morbidity and mortality globally. Hypercholesterolemia is one of the major risk factors for CHD. With the increase in aging populations and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2b ...

In fiscal year 2023, the managing heterozygous familial hypercholesterolemia (HEFH) management market is anticipated to be valued US$ 15.11 Billion, up from US$ 13.2 billion in fiscal year 2022. The ...

MarkNtel Advisors’ industry professionals present a comprehensive and professional study of the Hypercholesterolemia Market. The study is a perfect blend of quantitative and qualitative data tha ...

The extensive analysis of the market is based on key factors such as the historic and current market size, market share, market trends, competitive landscape, and growth opportunities. The report also ...

Cholesterol concentrations in many patients with familial hypercholesterolemia are poorly controlled despite dietary changes and maximum pharmacologic therapy. Increased concentrations of ...

Regeneron Pharmaceuticals Inc. (REGN) said that the U.S. Food and Drug Administration has approved Evkeeza (evinacumab-dgnb) to treat ...

Pharmacodynamics of the immune response will be measured by LDL cholesterol levels, an established model of PCSK9 inhibition in hypercholesterolemia. “We’re excited to get this first-in-human ...

Child–parent screening for familial hypercholesterolemia has been proposed to identify persons at high risk for inherited premature cardiovascular disease. We assessed the efficacy and ...

Vaxxinity expects to continue development of UB-311 with a strategic partner, focused on initiation of a pivotal trial supporting licensure. UB-312 targets toxic forms of aggregated a-synuclein in the ...